Dianthus Therapeutics
DNTH
94 hedge funds and large institutions have $211M invested in Dianthus Therapeutics in 2021 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 26 increasing their positions, 20 reducing their positions, and 16 closing their positions.
337% more capital inflows, than outflows
Capital inflows: $78.1M | Capital outflows: $17.9M
30% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 20
16.45% more ownership
Funds ownership: 64.72% → 81.17% (+16%)
1% more funds holding
Funds holding: 93 → 94 (+1)
6% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 16
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
94% less call options, than puts
Call options by funds: $3K | Put options by funds: $52K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$4.29M |
| 2 |
OrbiMed
New York
|
+$2.25M |
| 3 |
Principal Financial Group
Des Moines,
Iowa
|
+$718K |
| 4 |
BL
Bleichroeder LP
New York
|
+$314K |
| 5 |
State Street
Boston,
Massachusetts
|
+$259K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS AM
Chicago,
Illinois
|
-$3.72M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$3.48M |
| 3 |
Janus Henderson Group
London,
|
-$2.79M |
| 4 |
Woodline Partners
San Francisco,
California
|
-$1.58M |
| 5 |
EP
Eversept Partners
New York
|
-$1.45M |
DNTH Hedge Fund Activity: Q4 2021 in Review
94 of the 6,521 institutional investors tracked by Wall St. Rank reported a position in Dianthus Therapeutics (DNTH) for Q4 2021, worth a combined $211M — down 23% from $276M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new DNTH positions and 16 closed out — a net gain of 1 holder — while 26 added to existing stakes and 20 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $4.29M. The largest seller was UBS AM, exiting entirely with an estimated $3.72M sold.
- 94 institutional investors held Dianthus Therapeutics (DNTH) as of Q4 2021, up from 93 in Q3 2021.
- Funds reported $211M of Dianthus Therapeutics stock for Q4 2021, down 23% quarter-over-quarter.
- 17 funds opened new Dianthus Therapeutics positions in Q4 2021 and 16 closed out, a net change of +1 holder.
- The largest Dianthus Therapeutics buyer in Q4 2021 was Millennium Management, an estimated $4.29M added.
- The largest Dianthus Therapeutics seller in Q4 2021 was UBS AM, an estimated $3.72M sold.
Based on aggregated 13F filings for Q4 2021.